[10-Q] Benchmark Electronics Quarterly Earnings Report
Select Medical Holdings Corp. (SEM) Form 4: Chief Information Officer Brian R. Rusignuolo reported the grant of 75,000 shares of common stock on 29-Jul-2025. The award is restricted stock that will vest in full on 29-Jul-2028, subject to customary exceptions. No cash was paid (reported price $0), indicating an equity-based compensation grant rather than an open-market purchase.
Following the transaction, Rusignuolo鈥檚 direct beneficial ownership stands at 376,050 SEM shares. No derivative securities were involved and there were no dispositions.
- Form filed by one reporting person; no Rule 10b5-1 indication.
- Transaction code 鈥淎鈥� denotes an award rather than market activity.
- The grant aligns executive interests with shareholders but represents a small fraction of SEM鈥檚 outstanding shares (exact float not disclosed in the filing).
Select Medical Holdings Corp. (SEM) Modulo 4: Il Chief Information Officer Brian R. Rusignuolo ha segnalato la concessione di 75.000 azioni ordinarie il 29-lug-2025. Il premio 猫 costituito da azioni vincolate che matureranno completamente il 29-lug-2028, salvo le consuete eccezioni. Non 猫 stato pagato alcun importo in contanti (prezzo riportato $0), indicando una remunerazione basata su azioni piuttosto che un acquisto sul mercato aperto.
Dopo l'operazione, la propriet脿 diretta di Rusignuolo ammonta a 376.050 azioni SEM. Non sono stati coinvolti titoli derivati n茅 vi sono state cessioni.
- Modulo presentato da una sola persona segnalante; nessuna indicazione di Regola 10b5-1.
- Il codice transazione 鈥淎鈥� indica un premio e non un'attivit脿 di mercato.
- La concessione allinea gli interessi dell'esecutivo con quelli degli azionisti, ma rappresenta una piccola frazione delle azioni in circolazione di SEM (la quantit脿 esatta non 猫 stata divulgata nel modulo).
Select Medical Holdings Corp. (SEM) Formulario 4: El Director de Informaci贸n Brian R. Rusignuolo inform贸 la concesi贸n de 75,000 acciones ordinarias el 29-jul-2025. El premio consiste en acciones restringidas que se consolidar谩n completamente el 29-jul-2028, sujeto a excepciones habituales. No se pag贸 efectivo (precio reportado $0), lo que indica una compensaci贸n basada en acciones en lugar de una compra en el mercado abierto.
Tras la transacci贸n, la propiedad directa beneficiaria de Rusignuolo es de 376,050 acciones SEM. No hubo valores derivados involucrados ni disposiciones.
- Formulario presentado por una sola persona informante; sin indicaci贸n de la Regla 10b5-1.
- El c贸digo de transacci贸n 鈥淎鈥� denota un premio en lugar de actividad de mercado.
- La concesi贸n alinea los intereses ejecutivos con los de los accionistas, pero representa una peque帽a fracci贸n de las acciones en circulaci贸n de SEM (el n煤mero exacto no se divulg贸 en el formulario).
Select Medical Holdings Corp. (SEM) Form 4: 斓滉碃鞝曤炒毂呾瀯鞛� Brian R. Rusignuolo臧� 2025雲� 7鞗� 29鞚检棎 75,000欤检潣 氤错喌欤� 攵�鞐�毳� 鞁犼碃頄堨姷雼堧嫟. 鞚� 氤挫儊鞚� 鞝滍暅 欤检嫕鞙茧, 2028雲� 7鞗� 29鞚检棎 鞝勳暋 旆摑霅橂┌ 鞚茧皹鞝侅澑 鞓堨櫢臧� 鞝侅毄霅╇媹雼�. 順勱笀鞚� 歆�旮夒悩歆� 鞎婌晿鞙茧┌(氤搓碃霅� 臧�瓴� $0), 鞚措姅 瓿店皽 鞁滌灔鞐愳劀鞚� 甑Г臧� 鞎勲媽 欤检嫕 旮半皹 氤挫儊鞛勳潉 雮橅儉雰呺媹雼�.
瓯半灅 鞚错泟 Rusignuolo鞚� 歆侅爲 鞁れ 靻岇湢 欤检嫕鞚� 376,050 SEM 欤�鞛呺媹雼�. 韺岇儩 歃濌秾鞚� 韽暔霅橃 鞎婌晿鞙茧┌ 觳橂秳霃� 鞐嗢棃鞀惦媹雼�.
- 頃� 氇呾潣 鞁犼碃鞛愱皜 鞝滌稖頃� 鞏戩嫕; Rule 10b5-1 響滌嫓 鞐嗢潓.
- 瓯半灅 旖旊摐 鈥淎鈥濍姅 鞁滌灔 頇滊彊鞚� 鞎勲媽 氤挫儊鞚� 雮橅儉雰呺媹雼�.
- 鞚� 攵�鞐姅 瓴届榿歆勳潣 鞚挫澋鞚� 欤检＜鞕� 鞚检箻鞁滍偆歆�毵� SEM鞚� 鞙犿喌 欤检嫕 欷� 鞛戩潃 牍勳湪鞚� 彀頃╇媹雼�(鞝曧檿頃� 鞙犿喌霟夓潃 鞁犼碃靹滌棎 瓿店皽霅橃 鞎婌潓).
Select Medical Holdings Corp. (SEM) Formulaire 4 : Le Directeur de l'Information Brian R. Rusignuolo a d茅clar茅 l'octroi de 75 000 actions ordinaires le 29 juillet 2025. Cette attribution concerne des actions restreintes qui seront enti猫rement acquises le 29 juillet 2028, sous r茅serve des exceptions habituelles. Aucun paiement en esp猫ces n鈥檃 茅t茅 effectu茅 (prix d茅clar茅 0 $), ce qui indique une r茅mun茅ration en actions plut么t qu鈥檜n achat sur le march茅 libre.
Apr猫s la transaction, la propri茅t茅 directe b茅n茅ficiaire de Rusignuolo s鈥櫭﹍猫ve 脿 376 050 actions SEM. Aucun titre d茅riv茅 n鈥檃 茅t茅 impliqu茅 et aucune cession n鈥檃 eu lieu.
- Formulaire d茅pos茅 par une seule personne d茅clarant ; aucune indication de la r猫gle 10b5-1.
- Le code de transaction 芦 A 禄 d茅signe une attribution plut么t qu鈥檜ne activit茅 de march茅.
- L鈥檃ttribution aligne les int茅r锚ts de la direction avec ceux des actionnaires mais repr茅sente une faible fraction des actions en circulation de SEM (le nombre exact n鈥檈st pas divulgu茅 dans le formulaire).
Select Medical Holdings Corp. (SEM) Formular 4: Chief Information Officer Brian R. Rusignuolo meldete die Gew盲hrung von 75.000 Stammaktien am 29. Juli 2025. Die Zuwendung besteht aus eingeschr盲nkten Aktien, die am 29. Juli 2028 vollst盲ndig unverfallbar werden, vorbehaltlich 眉blicher Ausnahmen. Es wurde kein Bargeld gezahlt (gemeldeter Preis $0), was auf eine aktienbasierte Verg眉tung und keinen Kauf am offenen Markt hinweist.
Nach der Transaktion h盲lt Rusignuolo direkt 376.050 SEM-Aktien. Es waren keine Derivate involviert und es gab keine Ver盲u脽erungen.
- Formular wurde von einer meldenden Person eingereicht; keine Angabe zu Regel 10b5-1.
- Transaktionscode 鈥濧鈥� steht f眉r eine Zuwendung und nicht f眉r Marktaktivit盲ten.
- Die Gew盲hrung richtet die Interessen der F眉hrungskraft mit denen der Aktion盲re aus, stellt aber nur einen kleinen Bruchteil der ausstehenden SEM-Aktien dar (exakte Anzahl der Aktien im Umlauf wurde im Formular nicht offengelegt).
- Executive ownership increases by 75,000 shares, enhancing alignment between CIO and shareholders.
- None.
Insights
TL;DR: Executive awarded 75k restricted shares; modest, alignment-oriented, limited dilution鈥攏eutral market impact.
The filing documents a time-vested equity grant to the CIO. Such awards are typical for retention and incentive purposes. The additional 75k shares lift total insider holdings to 376k, signaling continued commitment but not an outright open-market buy. Because the shares come from equity incentive plans, dilution impact is de minimis relative to SEM鈥檚 overall share count. No pricing, derivative activity, or concurrent sales appear, so the transaction neither conveys strong bullish nor bearish insider sentiment. I classify the market impact as neutral.
Select Medical Holdings Corp. (SEM) Modulo 4: Il Chief Information Officer Brian R. Rusignuolo ha segnalato la concessione di 75.000 azioni ordinarie il 29-lug-2025. Il premio 猫 costituito da azioni vincolate che matureranno completamente il 29-lug-2028, salvo le consuete eccezioni. Non 猫 stato pagato alcun importo in contanti (prezzo riportato $0), indicando una remunerazione basata su azioni piuttosto che un acquisto sul mercato aperto.
Dopo l'operazione, la propriet脿 diretta di Rusignuolo ammonta a 376.050 azioni SEM. Non sono stati coinvolti titoli derivati n茅 vi sono state cessioni.
- Modulo presentato da una sola persona segnalante; nessuna indicazione di Regola 10b5-1.
- Il codice transazione 鈥淎鈥� indica un premio e non un'attivit脿 di mercato.
- La concessione allinea gli interessi dell'esecutivo con quelli degli azionisti, ma rappresenta una piccola frazione delle azioni in circolazione di SEM (la quantit脿 esatta non 猫 stata divulgata nel modulo).
Select Medical Holdings Corp. (SEM) Formulario 4: El Director de Informaci贸n Brian R. Rusignuolo inform贸 la concesi贸n de 75,000 acciones ordinarias el 29-jul-2025. El premio consiste en acciones restringidas que se consolidar谩n completamente el 29-jul-2028, sujeto a excepciones habituales. No se pag贸 efectivo (precio reportado $0), lo que indica una compensaci贸n basada en acciones en lugar de una compra en el mercado abierto.
Tras la transacci贸n, la propiedad directa beneficiaria de Rusignuolo es de 376,050 acciones SEM. No hubo valores derivados involucrados ni disposiciones.
- Formulario presentado por una sola persona informante; sin indicaci贸n de la Regla 10b5-1.
- El c贸digo de transacci贸n 鈥淎鈥� denota un premio en lugar de actividad de mercado.
- La concesi贸n alinea los intereses ejecutivos con los de los accionistas, pero representa una peque帽a fracci贸n de las acciones en circulaci贸n de SEM (el n煤mero exacto no se divulg贸 en el formulario).
Select Medical Holdings Corp. (SEM) Form 4: 斓滉碃鞝曤炒毂呾瀯鞛� Brian R. Rusignuolo臧� 2025雲� 7鞗� 29鞚检棎 75,000欤检潣 氤错喌欤� 攵�鞐�毳� 鞁犼碃頄堨姷雼堧嫟. 鞚� 氤挫儊鞚� 鞝滍暅 欤检嫕鞙茧, 2028雲� 7鞗� 29鞚检棎 鞝勳暋 旆摑霅橂┌ 鞚茧皹鞝侅澑 鞓堨櫢臧� 鞝侅毄霅╇媹雼�. 順勱笀鞚� 歆�旮夒悩歆� 鞎婌晿鞙茧┌(氤搓碃霅� 臧�瓴� $0), 鞚措姅 瓿店皽 鞁滌灔鞐愳劀鞚� 甑Г臧� 鞎勲媽 欤检嫕 旮半皹 氤挫儊鞛勳潉 雮橅儉雰呺媹雼�.
瓯半灅 鞚错泟 Rusignuolo鞚� 歆侅爲 鞁れ 靻岇湢 欤检嫕鞚� 376,050 SEM 欤�鞛呺媹雼�. 韺岇儩 歃濌秾鞚� 韽暔霅橃 鞎婌晿鞙茧┌ 觳橂秳霃� 鞐嗢棃鞀惦媹雼�.
- 頃� 氇呾潣 鞁犼碃鞛愱皜 鞝滌稖頃� 鞏戩嫕; Rule 10b5-1 響滌嫓 鞐嗢潓.
- 瓯半灅 旖旊摐 鈥淎鈥濍姅 鞁滌灔 頇滊彊鞚� 鞎勲媽 氤挫儊鞚� 雮橅儉雰呺媹雼�.
- 鞚� 攵�鞐姅 瓴届榿歆勳潣 鞚挫澋鞚� 欤检＜鞕� 鞚检箻鞁滍偆歆�毵� SEM鞚� 鞙犿喌 欤检嫕 欷� 鞛戩潃 牍勳湪鞚� 彀頃╇媹雼�(鞝曧檿頃� 鞙犿喌霟夓潃 鞁犼碃靹滌棎 瓿店皽霅橃 鞎婌潓).
Select Medical Holdings Corp. (SEM) Formulaire 4 : Le Directeur de l'Information Brian R. Rusignuolo a d茅clar茅 l'octroi de 75 000 actions ordinaires le 29 juillet 2025. Cette attribution concerne des actions restreintes qui seront enti猫rement acquises le 29 juillet 2028, sous r茅serve des exceptions habituelles. Aucun paiement en esp猫ces n鈥檃 茅t茅 effectu茅 (prix d茅clar茅 0 $), ce qui indique une r茅mun茅ration en actions plut么t qu鈥檜n achat sur le march茅 libre.
Apr猫s la transaction, la propri茅t茅 directe b茅n茅ficiaire de Rusignuolo s鈥櫭﹍猫ve 脿 376 050 actions SEM. Aucun titre d茅riv茅 n鈥檃 茅t茅 impliqu茅 et aucune cession n鈥檃 eu lieu.
- Formulaire d茅pos茅 par une seule personne d茅clarant ; aucune indication de la r猫gle 10b5-1.
- Le code de transaction 芦 A 禄 d茅signe une attribution plut么t qu鈥檜ne activit茅 de march茅.
- L鈥檃ttribution aligne les int茅r锚ts de la direction avec ceux des actionnaires mais repr茅sente une faible fraction des actions en circulation de SEM (le nombre exact n鈥檈st pas divulgu茅 dans le formulaire).
Select Medical Holdings Corp. (SEM) Formular 4: Chief Information Officer Brian R. Rusignuolo meldete die Gew盲hrung von 75.000 Stammaktien am 29. Juli 2025. Die Zuwendung besteht aus eingeschr盲nkten Aktien, die am 29. Juli 2028 vollst盲ndig unverfallbar werden, vorbehaltlich 眉blicher Ausnahmen. Es wurde kein Bargeld gezahlt (gemeldeter Preis $0), was auf eine aktienbasierte Verg眉tung und keinen Kauf am offenen Markt hinweist.
Nach der Transaktion h盲lt Rusignuolo direkt 376.050 SEM-Aktien. Es waren keine Derivate involviert und es gab keine Ver盲u脽erungen.
- Formular wurde von einer meldenden Person eingereicht; keine Angabe zu Regel 10b5-1.
- Transaktionscode 鈥濧鈥� steht f眉r eine Zuwendung und nicht f眉r Marktaktivit盲ten.
- Die Gew盲hrung richtet die Interessen der F眉hrungskraft mit denen der Aktion盲re aus, stellt aber nur einen kleinen Bruchteil der ausstehenden SEM-Aktien dar (exakte Anzahl der Aktien im Umlauf wurde im Formular nicht offengelegt).
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For the quarterly period ended
or
For the transition period from _________________ to________________
Commission File Number:
(Exact name of registrant as specified in its charter)
|
||
(State or other jurisdiction |
|
(I.R.S. Employer |
of incorporation or organization) |
|
Identification No.) |
|
|
|
|
||
|
(Zip Code) |
|
(Address of principal executive offices) |
|
|
(
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol |
Name of each exchange on which registered |
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
☑ |
|
Accelerated filer |
☐ |
|
Non-accelerated filer |
☐ |
|
Smaller reporting company |
|
|
|
|
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No
As of July 29, 2025, there were
TABLE OF CONTENTS
|
|
Page |
|
|
|
PART I—FINANCIAL INFORMATION |
||
|
|
|
Item 1. |
Financial Statements (Unaudited) |
1 |
|
Condensed Consolidated Balance Sheets |
1 |
|
Condensed Consolidated Statements of Income |
2 |
|
Condensed Consolidated Statements of Comprehensive Income |
3 |
|
Condensed Consolidated Statements of Shareholders’ Equity |
4 |
|
Condensed Consolidated Statements of Cash Flows |
5 |
|
Notes to the Condensed Consolidated Financial Statements |
6 |
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
23 |
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
32 |
Item 4. |
Controls and Procedures |
32 |
|
|
|
PART II—OTHER INFORMATION |
||
|
|
|
Item 1. |
Legal Proceedings |
34 |
Item 1A. |
Risk Factors |
34 |
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds |
34 |
Item 5. |
Other Information |
|
Item 6. |
Exhibits |
35 |
|
|
|
|
SIGNATURES |
36 |
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
BENCHMARK ELECTRONICS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(unaudited)
|
|
June 30, |
|
|
December 31, |
|
||
(in thousands, except par value) |
|
2025 |
|
|
2024 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
|
|
$ |
|
||
Restricted cash |
|
|
|
|
|
|
||
Accounts receivable, net of allowance for doubtful accounts of |
|
|
|
|
|
|
||
Contract assets |
|
|
|
|
|
|
||
Inventories |
|
|
|
|
|
|
||
Prepaid expenses and other current assets |
|
|
|
|
|
|
||
Total current assets |
|
|
|
|
|
|
||
Property, plant and equipment, net |
|
|
|
|
|
|
||
Operating lease right-of-use assets |
|
|
|
|
|
|
||
Goodwill |
|
|
|
|
|
|
||
Deferred income taxes |
|
|
|
|
|
|
||
Other long-term assets |
|
|
|
|
|
|
||
Total assets |
|
$ |
|
|
$ |
|
||
Liabilities and Shareholders’ Equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Current installments of long-term debt |
|
$ |
|
|
$ |
|
||
Accounts payable |
|
|
|
|
|
|
||
Advance payments from customers |
|
|
|
|
|
|
||
Income taxes payable |
|
|
|
|
|
|
||
Accrued liabilities |
|
|
|
|
|
|
||
Total current liabilities |
|
|
|
|
|
|
||
Long-term debt, net of current installments |
|
|
|
|
|
|
||
Operating lease liabilities |
|
|
|
|
|
|
||
Other long-term liabilities |
|
|
|
|
|
|
||
Deferred income taxes |
|
|
|
|
|
|
||
Total liabilities |
|
|
|
|
|
|
||
Shareholders’ equity: |
|
|
|
|
|
|
||
Preferred stock, $ |
|
|
|
|
|
|
||
Common stock, $ |
|
|
|
|
|
|
||
Additional paid-in capital |
|
|
|
|
|
|
||
Retained earnings |
|
|
|
|
|
|
||
Accumulated other comprehensive loss |
|
|
( |
) |
|
|
( |
) |
Total shareholders’ equity |
|
|
|
|
|
|
||
Total liabilities and shareholders’ equity |
|
$ |
|
|
$ |
|
||
See the accompanying notes to the unaudited condensed consolidated financial statements.
1
BENCHMARK ELECTRONICS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Income
(unaudited)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
(in thousands, except per share data) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Sales |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Cost of sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Gross profit |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Selling, general and administrative expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Amortization of intangible assets |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Restructuring charges and other costs |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Income from operations |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest expense |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Interest income |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other expense, net |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Income before income taxes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Income tax expense |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Diluted |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Weighted-average number of shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Diluted |
|
|
|
|
|
|
|
|
|
|
|
|
||||
See the accompanying notes to the unaudited condensed consolidated financial statements.
2
BENCHMARK ELECTRONICS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Income
(unaudited)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Net income |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Other comprehensive income: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Foreign currency translation adjustments |
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
||
Unrealized gain (loss) on derivatives, net of tax |
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
||
Other |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total other comprehensive income (loss) |
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
||
Comprehensive income |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
See the accompanying notes to the unaudited condensed consolidated financial statements.
3
BENCHMARK ELECTRONICS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Shareholders’ Equity
(unaudited)
(in thousands) |
|
Shares |
|
|
Common |
|
|
Additional |
|
|
Retained |
|
|
Accumulated |
|
|
Total |
|
||||||
Balances, December 31, 2024 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|||||
Net income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
||
Other comprehensive income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
||
Dividends declared |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Shares repurchased and retired |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
||
Stock options exercised |
|
|
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|||
Vesting of restricted stock units |
|
|
|
|
|
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
||
Shares withheld for taxes |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
Balances, June 30, 2025 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Balances, March 31, 2025 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|||||
Net income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
||
Other comprehensive income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
||
Dividends declared |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Shares repurchased and retired |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
||
Stock options exercised |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Vesting of restricted stock units |
|
|
|
|
|
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
||
Shares withheld for taxes |
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
Balances, June 30, 2025 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|||||
(in thousands) |
|
Shares |
|
|
Common |
|
|
Additional |
|
|
Retained |
|
|
Accumulated |
|
|
Total |
|
||||||
Balances, December 31, 2023 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|||||
Net income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
||
Other comprehensive loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Dividends declared |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
||
Stock options exercised |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
||||
Vesting of restricted stock units |
|
|
|
|
|
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
||
Shares withheld for taxes |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
Balances, June 30, 2024 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Balances, March 31, 2024 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|||||
Net income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
||
Other comprehensive loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Dividends declared |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
||
Stock options exercised |
|
|
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|||
Vesting of restricted stock units |
|
|
|
|
|
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
||
Shares withheld for taxes |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
Balances, June 30, 2024 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|||||
See the accompanying notes to the unaudited condensed consolidated financial statements.
4
BENCHMARK ELECTRONICS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(unaudited)
|
|
Six Months Ended |
|
|||||
(in thousands) |
|
2025 |
|
|
2024 |
|
||
Cash flows from operating activities: |
|
|
|
|
|
|
||
Net income |
|
$ |
|
|
$ |
|
||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: |
|
|
|
|
|
|
||
Depreciation |
|
|
|
|
|
|
||
Amortization |
|
|
|
|
|
|
||
Stock-based compensation expense |
|
|
|
|
|
|
||
Provision for doubtful accounts |
|
|
|
|
|
|
||
Deferred income taxes |
|
|
( |
) |
|
|
( |
) |
Loss on the sale of property, plant and equipment |
|
|
|
|
|
|
||
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
|
|
|
|
||
Contract assets |
|
|
( |
) |
|
|
( |
) |
Inventories |
|
|
|
|
|
|
||
Prepaid expenses and other assets |
|
|
( |
) |
|
|
( |
) |
Accounts payable |
|
|
( |
) |
|
|
( |
) |
Advance payments from customers |
|
|
( |
) |
|
|
( |
) |
Accrued liabilities |
|
|
( |
) |
|
|
( |
) |
Operating leases |
|
|
|
|
|
( |
) |
|
Income taxes |
|
|
( |
) |
|
|
|
|
Net cash provided by operating activities |
|
|
|
|
|
|
||
Cash flows from investing activities: |
|
|
|
|
|
|
||
Additions to property, plant and equipment |
|
|
( |
) |
|
|
( |
) |
Additions to capitalized purchased software |
|
|
( |
) |
|
|
( |
) |
Proceeds from the disposal of property, plant and equipment |
|
|
|
|
|
|
||
Other, net |
|
|
|
|
|
( |
) |
|
Net cash used in investing activities |
|
|
( |
) |
|
|
( |
) |
Cash flows from financing activities: |
|
|
|
|
|
|
||
Borrowings under credit agreement |
|
|
|
|
|
|
||
Principal payments on credit agreement |
|
|
( |
) |
|
|
( |
) |
Dividends paid |
|
|
( |
) |
|
|
( |
) |
Employee taxes paid with shares withheld |
|
|
( |
) |
|
|
( |
) |
Proceeds from stock options exercised |
|
|
|
|
|
|
||
Debt issuance costs |
|
|
( |
) |
|
|
|
|
Principal payments on finance leases |
|
|
( |
) |
|
|
( |
) |
Share repurchases |
|
|
( |
) |
|
|
|
|
Net cash used in financing activities |
|
|
( |
) |
|
|
( |
) |
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
|
|
|
|
|
( |
) |
|
Net (decrease) increase in cash, cash equivalents and restricted cash |
|
|
( |
) |
|
|
|
|
Cash, cash equivalents and restricted cash at the beginning of the year |
|
|
|
|
|
|
||
Cash, cash equivalents and restricted cash at the end of the period |
|
$ |
|
|
$ |
|
||
|
|
|
|
|
|
|
||
Supplemental cash flow information: |
|
|
|
|
|
|
||
Income taxes paid, net |
|
$ |
|
|
$ |
|
||
Interest paid |
|
|
|
|
|
|
||
Non-cash investing activities: |
|
|
|
|
|
|
||
Unpaid purchases of property, plant and equipment at the end of the period |
|
|
|
|
|
|
||
Unpaid purchases of capitalized purchased software costs at the end of the period |
|
|
|
|
|
|
||
See the accompanying notes to the unaudited condensed consolidated financial statements.
5
BENCHMARK ELECTRONICS, INC. AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(amounts in thousands, except per share data, unless otherwise noted)
(unaudited)
Note 1 – Basis of Presentation
Benchmark Electronics, Inc. (the Company) is a Texas corporation that provides advanced manufacturing services, which include design and engineering services and technology solutions. From initial product concept to volume production, including direct order fulfillment and aftermarket services, the Company has been providing integrated services and solutions to original equipment manufacturers (OEMs) since 1979. The Company serves the following market sectors: industrial, aerospace and defense (A&D), medical, semiconductor capital equipment (Semi-Cap), and advanced computing and communications (AC&C). The Company has manufacturing operations located in the United States and Mexico (the Americas), Asia and Europe.
The unaudited condensed consolidated financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the SEC) relating to interim financial statements. The condensed consolidated financial statements reflect all normal and recurring adjustments necessary in the opinion of management for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2024 (the 2024 10-K).
Management has made a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities to prepare these unaudited condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial statements. However, actual results could differ materially from these estimates.
Note 2 – New Accounting Pronouncements
In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-09, “Improvements to Income Tax Disclosures (Topic 740)” (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the guidance and its impact to the financial statements.
In November 2024, the FASB issued ASU 2024-03, “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” (ASU 2024-03), which requires public entities to disclose specified information about certain costs and expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026. Early adoption is permitted. The Company is currently evaluating the guidance and its impact to the financial statements.
Note 3 – Inventories
Inventory costs are summarized as follows:
|
|
June 30, |
|
|
December 31, |
|
||
(in thousands) |
|
2025 |
|
|
2024 |
|
||
Raw materials |
|
$ |
|
|
$ |
|
||
Work in process |
|
|
|
|
|
|
||
Finished goods |
|
|
|
|
|
|
||
Total inventories |
|
$ |
|
|
$ |
|
||
6
Note 4 – Goodwill and Other Intangible Assets
Goodwill allocated to the Company’s reportable operating segments follows:
(in thousands) |
|
Americas |
|
|
Asia |
|
|
Total |
|
|||
Goodwill as of June 30, 2025 and December 31, 2024 |
|
$ |
|
|
$ |
|
|
$ |
|
|||
A summary of the Company’s acquired identifiable intangible assets and capitalized purchased software costs follows:
(in thousands) |
|
Gross |
|
|
Accumulated |
|
|
Net |
|
|||
Customer relationships |
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||
Capitalized purchased software costs |
|
|
|
|
|
( |
) |
|
|
|
||
Technology licenses |
|
|
|
|
|
( |
) |
|
|
|
||
Trade names and trademarks |
|
|
|
|
|
|
|
|
|
|||
Other |
|
|
|
|
|
( |
) |
|
|
|
||
Total intangible assets as of June 30, 2025 |
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||
(in thousands) |
|
Gross |
|
|
Accumulated |
|
|
Net |
|
|||
Customer relationships |
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||
Capitalized purchased software costs |
|
|
|
|
|
( |
) |
|
|
|
||
Technology licenses |
|
|
|
|
|
( |
) |
|
|
|
||
Trade names and trademarks |
|
|
|
|
|
|
|
|
|
|||
Other |
|
|
|
|
|
( |
) |
|
|
|
||
Total intangible assets as of December 31, 2024 |
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||
A summary of the components of amortization expense, as presented in the consolidated statements of cash flows, follows:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Amortization of intangible assets |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Amortization of capitalized purchased software costs |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Amortization of debt costs |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total amortization expense |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
A summary of the future amortization expense related to the Company’s intangible assets held as of June 30, 2025 for each of the next five years follows (in thousands):
Year ending December 31, |
|
Amortization |
|
|
Remaining six months of 2025 |
|
$ |
|
|
2026 |
|
|
|
|
2027 |
|
|
|
|
2028 |
|
|
|
|
2029 |
|
|
|
|
2030 |
|
|
|
|
7
Note 5 – Borrowing Facilities
Long-term debt consists of the following:
|
|
June 30, |
|
|
December 31, |
|
||
(in thousands) |
|
2025 |
|
|
2024 |
|
||
Revolving credit facility |
|
$ |
|
|
$ |
|
||
Term loan |
|
|
|
|
|
|
||
Less: unamortized debt issuance costs |
|
|
( |
) |
|
|
( |
) |
Total long-term debt, including current installments |
|
$ |
|
|
$ |
|
||
The Credit Agreement amended and restated in its entirety the Company’s previous $
The Credit Agreement includes an accordion feature pursuant to which the Company is permitted to add one or more incremental term loans and/or increase commitments under the Revolving Credit Facility in an aggregate amount not exceeding $
The Revolving Credit Facility is available for general corporate purposes. Principal under the Term Loan Facility will amortize in equal
Interest on outstanding borrowings under the Credit Agreement (other than swingline loans) will accrue, at the Company’s option, at (a) Term Secured Overnight Financing Rate (Term SOFR) plus the Applicable Rate (as defined in the Credit Agreement, approximately
As of June 30, 2025, a portion of the $
The Credit Agreement is generally secured by a pledge of (a) all the capital stock of the Company’s domestic subsidiaries and
8
As of June 30, 2025, the Company had $
Note 6 – Leases
The Company determines if a contract is or contains a lease at inception. The Company leases certain facilities, vehicles and other equipment. The Company’s leases primarily consist of operating leases which expire at various dates through 2036. Variable lease payments are generally expensed as incurred and primarily include certain index-based changes in rent and certain non-lease components, such as maintenance and other services provided by the lessor.
The components of lease expense were as follows:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Finance lease costs: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest on lease liabilities |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Operating lease costs |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Short-term lease costs |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Variable lease costs |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total lease costs |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
A summary of cash flow information related to leases follows:
|
Six Months Ended |
|
|||||
(in thousands) |
2025 |
|
|
2024 |
|
||
Cash paid for amounts included in the measurement of lease liabilities: |
|
|
|
|
|
||
Operating cash flows used for operating leases |
$ |
|
|
$ |
|
||
Operating cash flows used for finance leases |
|
|
|
|
|
||
Financing cash flows used for finance leases |
|
|
|
|
|
||
Right-of-use assets obtained in exchange for new operating lease liabilities |
|
|
|
|
|
||
A summary of other information about the Company's leases follows:
|
|
June 30, |
|
|
December 31, |
|
||
(dollars in thousands) |
|
2025 |
|
|
2024 |
|
||
Operating lease right-of-use assets |
|
$ |
|
|
$ |
|
||
Finance lease liabilities, current (included in current installments of long-term debt) |
|
$ |
|
|
$ |
|
||
Operating lease liabilities, current (included in accrued liabilities) |
|
$ |
|
|
$ |
|
||
Operating lease liabilities, noncurrent |
|
$ |
|
|
$ |
|
||
Weighted average remaining lease term – finance leases |
|
|
|
|
||||
Weighted average remaining lease term – operating leases |
|
|
|
|
||||
Weighted average discount rate – finance leases |
|
|
% |
|
|
% |
||
Weighted average discount rate – operating leases |
|
|
% |
|
|
% |
||
9
A summary of the Company's future annual minimum lease payments as of June 30, 2025 follows (in thousands):
Year ending December 31, |
|
Operating |
|
|
Finance |
|
||
Remaining six months of 2025 |
|
$ |
|
|
$ |
|
||
2026 |
|
|
|
|
|
|
||
2027 |
|
|
|
|
|
|
||
2028 |
|
|
|
|
|
|
||
2029 |
|
|
|
|
|
|
||
2030 and thereafter |
|
|
|
|
|
|
||
Total minimum lease payments |
|
|
|
|
|
|
||
Less: imputed interest |
|
|
( |
) |
|
|
( |
) |
Total present value of lease liabilities |
|
$ |
|
|
$ |
|
||
Note 7 – Common Stock and Stock-Based Awards
Dividends
For the three and six months ended June 30, 2025, cash dividends paid totaled $
On June 9, 2025, the Company declared a quarterly cash dividend of $
The Board of Directors currently intends to continue to pay quarterly dividends. However, the Company’s future dividend policy is subject to the Company’s compliance with applicable laws, and depends on, among other things, the Company’s results of operations, financial condition, level of indebtedness, capital requirements, contractual restrictions, restrictions in the Company’s debt agreements, and other factors that the Board of Directors may deem relevant. Dividend payments are not mandatory or guaranteed and no assurance is made that the Company will continue to pay a dividend in the future.
Share Repurchase Authorization
On February 19, 2020, the Board of Directors approved an expanded share repurchase authorization granting the Company authority to repurchase up to $
Share purchases may be made in the open market, in privately negotiated transactions or block transactions, at the discretion of the Company’s management and as market conditions warrant. Purchases will be funded from available cash and may be commenced, suspended or discontinued at any time without prior notice. Shares repurchased under the program are retired.
The Company repurchased
Stock-Based Compensation
Under the 2019 Omnibus Incentive Compensation Plan (as amended, the 2019 Plan), the Company, upon approval of the Compensation Committee of the Board of Directors, may grant stock options, restricted shares, restricted stock units (both time-based and performance-based) and certain other forms of equity awards, or any combination thereof, to any director, officer, employee or consultant (including any prospective director, officer, employee or consultant) of the Company. Stock options (which have not been awarded since 2015) are granted to employees with an exercise price equal to the market price of the Company’s common stock on the date of grant, generally vest over a
10
All share-based payments to employees of the Company, including grants of employee stock options (last awarded in 2015), are recognized in the consolidated financial statements based on their grant date fair values. The total compensation costs recognized for stock-based awards were $
As of June 30, 2025, the unrecognized compensation costs and remaining weighted-average amortization periods related to stock-based awards were as follows:
(in thousands) |
|
Time- |
|
|
Performance- |
|
||
Unrecognized compensation cost |
|
$ |
|
|
$ |
|
||
Remaining weighted-average amortization period |
|
|
|
|
||||
(1)
The total cash received by the Company as a result of stock option exercises for the six months ended June 30, 2025 and 2024 was less than $
For performance-based restricted stock units granted during the six months ended June 30, 2025 and 2024, the number of performance-based restricted stock units that will ultimately be earned will not be determined until the end of the respective performance periods, and may vary from as low as zero to as high as 2.5 times the target number depending on the level of achievement of certain performance goals. The level of achievement of these goals is based upon the financial results of the Company for the last full calendar year within the performance period. The performance goals consist of certain levels of achievement using the following financial metrics: revenue, operating income margin, and return on invested capital. If the performance goals are not met based on the Company’s financial results, the applicable performance-based restricted stock units will not vest and will be forfeited. Shares subject to forfeited performance-based restricted stock units will be available for re-issuance under the Company’s 2019 Plan.
The following table summarizes activities relating to the Company’s stock options:
(in thousands, except per share data and years) |
|
Number of |
|
|
Weighted- |
|
|
Weighted- |
|
|
Aggregate |
|
||||
Outstanding as of December 31, 2024 |
|
|
|
|
$ |
|
|
|
|
|
|
|
||||
Exercised |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|||
Outstanding and exercisable as of June 30, 2025 |
|
|
|
|
|
|
|
|
— |
|
|
$ |
|
|||
11
The following table summarizes the activities related to the Company’s time-based restricted stock units:
(in thousands, except per share data) |
|
Number of |
|
|
Weighted- |
|
||
Non-vested awards outstanding as of December 31, 2024 |
|
|
|
|
$ |
|
||
Granted |
|
|
|
|
|
|
||
Vested |
|
|
( |
) |
|
|
|
|
Forfeited |
|
|
( |
) |
|
|
|
|
Non-vested awards outstanding as of June 30, 2025 |
|
|
|
|
|
|
||
The following table summarizes the activities related to the Company’s performance-based restricted stock units:
(in thousands, except per share data) |
|
Number of |
|
|
Weighted- |
|
||
Non-vested awards outstanding as of December 31, 2024 |
|
|
|
|
$ |
|
||
Granted(1) |
|
|
|
|
|
|
||
Vested |
|
|
( |
) |
|
|
|
|
Forfeited |
|
|
( |
) |
|
|
|
|
Non-vested awards outstanding as of June 30, 2025 |
|
|
|
|
|
|
||
(1)
Note 8 – Earnings Per Share
Basic earnings per share is computed using the weighted-average number of common shares outstanding. Diluted earnings per share is computed using the weighted-average number of common shares outstanding adjusted for the incremental shares attributed to outstanding stock equivalents. Stock equivalents include common shares issuable upon the exercise of stock options and other equity instruments and are computed using the treasury stock method. Under the treasury stock method, the exercise price of a share and the amount of compensation cost, if any, for future service that the Company has not yet recognized are assumed to be used to repurchase shares in the current period.
The following table sets forth the calculation of the Company’s basic and diluted earnings per share:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
(in thousands, except per share data) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Net income |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Denominator for basic earnings per share |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Incremental common shares attributable to outstanding restricted stock units |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Incremental common shares attributable to exercise of dilutive options |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Denominator for diluted earnings per share |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Diluted |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Restricted stock units totaling less than
12
Note 9 – Income Taxes
Income tax expense consists of the following:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Income before income taxes |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Income tax expense |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Effective tax rate |
|
|
% |
|
|
% |
|
|
% |
|
|
% |
||||
During the three months ended June 30, 2025, the Company, as part of its ongoing assessment of global liquidity needs, evaluated the cash balances held in foreign jurisdictions relative to anticipated operational and investment requirements. Driven by a time-sensitive opportunity to recover foreign withholding taxes, along with the Company’s debt refinancing and cash diversification objectives, the Company repatriated gross dividends of $
As part of this evaluation, the Company determined that current and projected cash balances in China exceeded the levels required to fund local business activities. As a result, management changed its assertion with respect to remaining unremitted earnings from China, which are now considered available for distribution. There was no change to the Company’s indefinite reinvestment assertion with respect to Thailand.
Accordingly, during the three months ended June 30, 2025, the Company recorded discrete tax charges totaling $
The Company’s effective income tax rate was
The Company’s effective income tax rate was
The Company has been granted certain tax incentives, including tax holidays, for its subsidiaries in Thailand and China that expire at various dates, unless extended or otherwise renegotiated and are subject to certain conditions with which the Company expects to comply. The tax incentives in Thailand will expire at various dates through December 31, 2030. In the fourth quarter of 2024, the Company was awarded a China tax holiday retroactive to January 1, 2024 through December 31, 2026. The tax holiday reduces the statutory tax rate from
A summary of the Company’s tax incentives follows:
|
|
Six Months Ended |
|
|||||
(in thousands) |
|
2025 |
|
|
2024 |
|
||
Thailand |
|
$ |
|
|
$ |
|
||
China |
|
|
|
|
|
|
||
Total tax incentives |
|
$ |
|
|
$ |
|
||
In April 2025, the Company fully paid its remaining transition tax liability of $
On July 4, 2025, the U.S. government enacted The One Big Beautiful Bill Act of 2025 which includes, among other provisions, changes to the U.S. corporate income tax system including the allowance of immediate expensing of qualifying research and
13
development expenses and permanent extensions of certain provisions within the Tax Cuts and Jobs Act. The legislation has multiple effective dates, with certain provisions effective in 2025. The Company is evaluating the future impact of these tax law changes on its financial statements.
Determining the consolidated income tax expense, income tax liabilities and deferred tax assets and liabilities involves judgment. The Company calculates and provides for income taxes in each of the tax jurisdictions in which the Company operates, which involves estimating current tax exposures as well as making judgments regarding the recoverability of deferred tax assets in each jurisdiction. The estimates used could differ from actual results, which may have a significant impact on operating results in future periods.
Note 10 – Revenue
The Company’s revenues are generated primarily from its manufacturing services, which entails the sale of manufactured products built to customer specifications. The Company also generates revenue from design, development and engineering services, in addition to the sale of other inventory.
Revenue is measured based on the consideration specified in a contract with a customer. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a manufactured product to a customer. The Company’s contracts with customers are generally short-term in nature. Customers are generally billed when the product is shipped or as services are performed. Under the majority of the Company’s manufacturing contracts with customers, the customer controls all of the work-in-progress as products are being built. Revenues under these contracts are recognized progressively based on the cost-to-cost method. For other manufacturing contracts, the customer does not take control of the product until it is completed. Under these contracts, the Company recognizes revenue upon transfer of control of the product to the customer, which is generally when goods are shipped. Revenue from design, development and engineering services is recognized over time as the services are performed. The Company assumes no significant obligations after shipment as it typically warrants workmanship only. Therefore, the warranty provisions are generally not significant.
If the Company records revenue, but does not issue an invoice, a contract asset is recognized. The contract asset is transferred to trade accounts receivable when the entitlement to payment becomes unconditional.
Taxes assessed by governmental authorities that are imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer, are excluded from revenue.
Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as fulfillment costs and are included in cost of sales.
Disaggregation of Revenue
The following tables provide a summary of the Company’s revenue disaggregated by market sector and a reconciliation of the disaggregated revenue to the Company’s revenue by reportable operating segment:
|
|
Three Months Ended June 30, 2025 |
|
|||||||||||||
(in thousands) |
|
Americas |
|
|
Asia |
|
|
Europe |
|
|
Total |
|
||||
Market sector: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Semi-Cap |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Industrial |
|
|
|
|
|
|
|
|
|
|
|
|
||||
A&D |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Medical |
|
|
|
|
|
|
|
|
|
|
|
|
||||
AC&C |
|
|
|
|
|
|
|
|
|
|
|
|
||||
External revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Elimination of intersegment sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Segment revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
14
|
|
Six Months Ended June 30, 2025 |
|
|||||||||||||
(in thousands) |
|
Americas |
|
|
Asia |
|
|
Europe |
|
|
Total |
|
||||
Market sector: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Semi-Cap |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Industrial |
|
|
|
|
|
|
|
|
|
|
|
|
||||
A&D |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Medical |
|
|
|
|
|
|
|
|
|
|
|
|
||||
AC&C |
|
|
|
|
|
|
|
|
|
|
|
|
||||
External revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Elimination of intersegment sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Segment revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
Three Months Ended June 30, 2024 |
|
|||||||||||||
(in thousands) |
|
Americas |
|
|
Asia |
|
|
Europe |
|
|
Total |
|
||||
Market sector: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Semi-Cap |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Industrial |
|
|
|
|
|
|
|
|
|
|
|
|
||||
A&D |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Medical |
|
|
|
|
|
|
|
|
|
|
|
|
||||
AC&C |
|
|
|
|
|
|
|
|
|
|
|
|
||||
External revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Elimination of intersegment sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Segment revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
Six Months Ended June 30, 2024 |
|
|||||||||||||
(in thousands) |
|
Americas |
|
|
Asia |
|
|
Europe |
|
|
Total |
|
||||
Market sector: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Semi-Cap |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Industrial |
|
|
|
|
|
|
|
|
|
|
|
|
||||
A&D |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Medical |
|
|
|
|
|
|
|
|
|
|
|
|
||||
AC&C |
|
|
|
|
|
|
|
|
|
|
|
|
||||
External revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Elimination of intersegment sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Segment revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
The timing of revenue recognition, billings and cash collections results in billed accounts receivable, contract assets and advance payments from customers. During the six months ended June 30, 2025 and 2024,
Contract assets primarily relate to the Company’s right to consideration for work completed but not billed to the customer as of period end. Contract asset balances are transferred to trade accounts receivable when the rights become unconditional.
A summary of activity related to the Company’s contract assets follows:
|
|
Six Months Ended |
|
|||||
(in thousands) |
|
2025 |
|
|
2024 |
|
||
Balance as of the beginning of the year |
|
$ |
|
|
$ |
|
||
Revenue recognized |
|
|
|
|
|
|
||
Amounts collected or invoiced |
|
|
( |
) |
|
|
( |
) |
Balance as of the end of the period |
|
$ |
|
|
$ |
|
||
15
As of June 30, 2025 and December 31, 2024, the Company had $
Note 11 – Segment and Geographic Information
The Company’s Chief Executive Officer is our Chief Operating Decision Maker (CODM) who evaluates how resources are allocated, assesses performance and makes strategic and operational decisions. The Company currently has manufacturing facilities in the Americas, Asia and Europe to serve its customers. The Company is operated and managed geographically, and management evaluates performance and allocates the Company’s resources on a geographic basis. We provide manufacturing services, design and engineering services, and technology solutions in the Americas, Asia and Europe. Intersegment sales are generally recorded at prices that approximate arm’s length transactions.
Information about the Company’s operating segments follows:
|
|
Three Months Ended June 30, 2025 |
|
|||||||||||||
(in thousands) |
|
Americas |
|
|
Asia |
|
|
Europe |
|
|
Total |
|
||||
Sales from external customers |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Intersegment sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Reconciliation of sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Elimination of intersegment sales |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Sales |
|
|
|
|
|
|
|
|
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Less: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Selling, general and administrative expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other(1) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Segment income from operations |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Reconciliation of income before income taxes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other - corporate and eliminations(2) |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Interest income |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other expense, net |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Income before income taxes |
|
|
|
|
|
|
|
|
|
|
$ |
|
||||
16
|
|
Six Months Ended June 30, 2025 |
|
|||||||||||||
(in thousands) |
|
Americas |
|
|
Asia |
|
|
Europe |
|
|
Total |
|
||||
Sales from external customers |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Intersegment sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Reconciliation of sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Elimination of intersegment sales |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Sales |
|
|
|
|
|
|
|
|
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Less: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Selling, general and administrative expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other(1) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Segment income from operations |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Reconciliation of income before income taxes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other - corporate and eliminations(2) |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Interest income |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other expense, net |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Income before income taxes |
|
|
|
|
|
|
|
|
|
|
$ |
|
||||
|
|
Three Months Ended June 30, 2024 |
|
|||||||||||||
(in thousands) |
|
Americas |
|
|
Asia |
|
|
Europe |
|
|
Total |
|
||||
Sales from external customers |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Intersegment sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Reconciliation of sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Elimination of intersegment sales |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Sales |
|
|
|
|
|
|
|
|
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Less: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Selling, general and administrative expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other(1) |
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|||
Segment income from operations |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Reconciliation of income before income taxes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other - corporate and eliminations(2) |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Interest income |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other expense, net |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Income before income taxes |
|
|
|
|
|
|
|
|
|
|
$ |
|
||||
17
|
|
Six Months Ended June 30, 2024 |
|
|||||||||||||
(in thousands) |
|
Americas |
|
|
Asia |
|
|
Europe |
|
|
Total |
|
||||
Sales from external customers |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Intersegment sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Reconciliation of sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Elimination of intersegment sales |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Sales |
|
|
|
|
|
|
|
|
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Less: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Selling, general and administrative expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other(1) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Segment income from operations |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Reconciliation of income before income taxes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other - corporate and eliminations(2) |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Interest income |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other expense, net |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|||
Income before income taxes |
|
|
|
|
|
|
|
|
|
|
$ |
|
||||
(1)
(2)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Depreciation and amortization: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Americas |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Asia |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Europe |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Corporate |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total depreciation and amortization |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Capital expenditures: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Americas |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Asia |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Europe |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Corporate |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total capital expenditures |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
|
|
|
|
June 30, |
|
|
December 31, |
|
||
(in thousands) |
|
|
|
|
|
2025 |
|
|
2024 |
|
||
Assets: |
|
|
|
|
|
|
|
|
|
|
||
Americas |
|
|
|
|
|
$ |
|
|
$ |
|
||
Asia |
|
|
|
|
|
|
|
|
|
|
||
Europe |
|
|
|
|
|
|
|
|
|
|
||
Corporate |
|
|
|
|
|
|
|
|
|
|
||
Total assets |
|
|
|
|
|
$ |
|
|
$ |
|
||
18
Geographic sales information about the Company’s sales is determined based on the destination of the product shipped. Long-lived assets information is determined based on the physical location of the Company’s assets and includes property, plant and equipment, net, operating lease right-of-use assets and other long-term assets, net.
A summary of the Company’s geographic sales and long-lived assets follows:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Geographic sales: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
United States |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Singapore |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other Asia |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Europe |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total sales |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
|
|
|
|
June 30, |
|
|
December 31, |
|
||
(in thousands) |
|
|
|
|
|
2025 |
|
|
2024 |
|
||
Long-lived assets: |
|
|
|
|
|
|
|
|
|
|
||
United States |
|
|
|
|
|
$ |
|
|
$ |
|
||
Asia |
|
|
|
|
|
|
|
|
|
|
||
Europe |
|
|
|
|
|
|
|
|
|
|
||
Other |
|
|
|
|
|
|
|
|
|
|
||
Total long-lived assets |
|
|
|
|
|
$ |
|
|
$ |
|
||
Note 12 – Accounts Receivable Sale Programs
As of June 30, 2025, in connection with trade accounts receivable sale programs with unaffiliated financial institutions, the Company may elect to sell, at a discount, on an ongoing basis, up to a maximum of $
During the three months ended June 30, 2025 and 2024, the Company sold $
During the six months ended June 30, 2025 and 2024, the Company sold $
The Company recognizes the loss on sale resulting from the discount in other expense, net in its consolidated statements of income.
Note 13 – Financial Instruments
The Company’s financial instruments include cash equivalents, accounts receivable, other receivables, accounts payable, accrued liabilities, long-term debt, interest rate swaps and foreign currency hedges. For cash equivalents, accounts receivable, other receivables, accounts payable and accrued liabilities, the Company believes that the carrying values of its financial instruments approximate the fair values because of their short-term nature. For borrowings under the Credit Agreement in long-term debt, the Company believes that the fair value approximates the carrying value because the interest rates are variable. The Company uses derivative instruments to manage the variability of foreign currency obligations and interest rates. The Company does not enter into derivatives for speculative purposes.
19
The fair value of the Company’s derivative instruments follows:
|
|
|
|
June 30, |
|
|
December 31, |
|
||
(in thousands) |
|
Balance Sheet Location |
|
2025 |
|
|
2024 |
|
||
Derivatives designated as hedging instruments: |
|
|
|
|
|
|
|
|
||
Forward currency exchange contracts |
|
Other long-term assets |
|
$ |
|
|
$ |
|
||
Forward currency exchange contracts |
|
Other long-term liabilities |
|
|
|
|
|
|
||
Interest rate swap agreement |
|
Other long-term liabilities |
|
|
|
|
|
|
||
Forward Currency Exchange Contracts
The Company utilizes forward currency exchange contracts to manage its foreign currency exposure. The Company enters into forward currency exchange contracts for its operations in Mexico, Europe and Asia. These instruments are designated as cash flow hedges and the changes in fair value of the derivatives are recorded in accumulated other comprehensive loss on the consolidated balance sheet until earnings are affected by the variability of the cash flows. The fair value estimates for the Company’s forward currency exchange contracts are based on Level 2 inputs of the fair value hierarchy, which includes obtaining directly or indirectly observable values from third parties active in the relevant markets. Inputs in the fair value of the foreign currency forward contracts include prevailing forward and spot prices for currencies.
During the three and six months ended June 30, 2025, the Company recorded an unrealized gain of $
During the three and six months ended June 30, 2024, the Company recorded an unrealized loss of $
The Company also has forward currency exchange contracts that have not been designated as accounting hedges and, therefore, changes in fair value are recorded in other expense, net in the consolidated statements of income.
Interest Rate Swap Agreement
The Company utilizes an interest rate swap agreement to hedge a portion of its interest rate exposure on outstanding borrowings under the Credit Agreement. Under the interest rate swap agreement, the Company receives variable rate interest payments based on the one-month Term SOFR rate and pays fixed rate interest payments. The effect of the swap is to convert a portion of the floating rate interest expense to fixed interest rate expense. Based on the terms of the interest rate swap contract and the underlying borrowings outstanding under the Credit Agreement, the interest rate swap was determined to be highly effective, and thus qualifies and has been designated as a cash flow hedge. As such, changes in the fair value of the interest rate swap are recorded in accumulated other comprehensive loss on the consolidated balance sheet until earnings are affected by the variability of cash flows. The fair value estimates for the Company’s respective interest rate swap agreements were based on Level 2 inputs of the fair value hierarchy, as the Company obtains the valuation from a third party active in relevant markets. The valuation of the interest rate swap agreements is primarily measured through various pricing models and discounted cash flow analysis that incorporate observable market parameters, such as interest rate yield curves and volatility.
The Company entered into an interest rate swap agreement on July 20, 2023 and the fixed interest rate for the contract is
During the three and six months ended June 30, 2025, the Company recorded an unrealized loss of $
During the three and six months ended June 30, 2024, the Company recorded an unrealized gain of $
20
Note 14 – Accumulated Other Comprehensive Loss
A summary of the changes in accumulated other comprehensive loss follows:
|
|
Three Months Ended June 30, |
|
|||||||||||||||||||||||||||||
|
|
2025 |
|
|
2024 |
|
||||||||||||||||||||||||||
(in thousands) |
|
Foreign |
|
|
Derivative |
|
|
Other |
|
|
Total |
|
|
Foreign |
|
|
Derivative |
|
|
Other |
|
|
Total |
|
||||||||
Beginning balance |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
Other comprehensive gain (loss) before reclassifications |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
( |
) |
|||||
Amounts reclassified from accumulated other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
||||||
Total other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
( |
) |
|||||
Ending balance |
|
$ |
( |
) |
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
|
|
Six Months Ended June 30, |
|
|||||||||||||||||||||||||||||
|
|
2025 |
|
|
2024 |
|
||||||||||||||||||||||||||
(in thousands) |
|
Foreign |
|
|
Derivative |
|
|
Other |
|
|
Total |
|
|
Foreign |
|
|
Derivative |
|
|
Other |
|
|
Total |
|
||||||||
Beginning balance |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
Other comprehensive gain (loss) before reclassifications |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
( |
) |
||||||
Amounts reclassified from accumulated other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
||||||
Total other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
( |
) |
|||||
Ending balance |
|
$ |
( |
) |
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
See Note 13 for further discussion about the Company’s derivative instruments.
21
Note 15 – Contingencies
On January 7, 2025, our Guadalajara subsidiary Benchmark Electronics de Mexico S. de R.L. de C.V. (Benchmark Guadalajara) received a tax assessment from the Jalisco, Mexico office of customs and taxing authorities (Servicio de Administracion Tributaria (SAT)) asserting that Benchmark Guadalajara owed approximately $
The Company is involved in various legal actions arising in the ordinary course of business. Although the outcome of these matters cannot be predicted with certainty, in the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position or results of operations.
Note 16 – Restructuring Charges and Other Costs
The Company has undertaken initiatives to restructure its business operations to improve utilization and realize cost savings. These initiatives have included changing the number and location of production facilities, largely to align capacity and infrastructure with current and anticipated customer demand. This alignment includes transferring programs from higher cost geographies to lower cost geographies. The Company’s restructuring process entails moving production between facilities, reducing staff levels, realigning business processes, reorganizing management and other activities.
During the six months ended June 30, 2025, the Company recognized $
The Company recognized $
The components of restructuring charges were as follows:
|
|
Six Months Ended June 30, 2025 |
|
|||||||||||||
(in thousands) |
|
Americas |
|
|
Asia |
|
|
Europe |
|
|
Total |
|
||||
Severance costs |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Other exit costs |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total restructuring charges |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
The changes in the Company’s accrued restructuring costs were as follows:
(in thousands) |
|
Balances as of |
|
|
Restructuring |
|
|
Cash |
|
|
Non-Cash |
|
|
Balances as of |
|
|||||
Severance costs |
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|
$ |
|
||||
Other exit costs |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
||||
Total accrued restructuring costs |
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|
$ |
|
||||
22
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The financial information and the discussion below should be read in conjunction with other information, including the unaudited condensed consolidated financial statements and Notes thereto in Part I, Item 1 of this quarterly report on Form 10-Q for the quarterly period ended June 30, 2025 (this Report), the consolidated financial statements and Notes thereto appearing in the Company’s annual report on Form 10-K for the year ended December 31, 2024 (the 2024 10-K), and Part I, Item 1A, Risk Factors of the 2024 10-K. In this Report, references to Benchmark, the Company or use of the words “we,” “our” and “us” include Benchmark’s subsidiaries unless otherwise noted.
This Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These forward-looking statements are identified as any statement that does not relate strictly to historical or current facts and may include words such as “anticipate,” “believe,” “intend,” “plan,” “project,” “forecast,” “strategy,” “position,” “continue,” “estimate,” “expect,” “may,” “will,” “could,” “predict,” and similar expressions of the negative or other variations thereof. In particular, statements, expressed or implied, concerning the Company's outlook and guidance for quarterly periods or fiscal year 2025 results, future operating results or margins, the ability to generate sales and income or cash flow, expected revenue mix, the Company’s business strategy and strategic initiatives, the Company’s repurchases of shares of its common stock, the Company’s expectations regarding restructuring charges, stock-based compensation expense, amortization of intangibles, award of any tax incentives and capital expenditures, and the Company’s intentions concerning the payment of dividends, among others, are forward-looking statements. Although the Company believes these statements are based on and derived from reasonable assumptions, they involve risks, uncertainties and assumptions, that are beyond the Company’s ability to control or predict, relating to operations, markets and the business environment generally, including those discussed under Part I, Item 1A of the 2024 10-K and in any of the Company’s subsequent reports filed with the Securities and Exchange Commission (the SEC). Events relating to the possibility of customer demand fluctuations, supply chain constraints, continuing inflationary pressures, the effects of foreign currency fluctuations and high interest rates, geopolitical uncertainties including continuing hostilities and tensions, trade restrictions and sanctions, tariffs and retaliatory countermeasures, the ability to utilize the Company’s manufacturing facilities at sufficient levels to cover its fixed operating costs, or write-downs or write-offs of obsolete or unsold inventory, may have resulting impacts on the Company’s business, financial condition, results of operations, and the Company’s ability (or inability) to execute on its plans. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes, including the future results of the Company’s operations, may vary materially from those indicated. Undue reliance should not be placed on any forward-looking statements. Forward-looking statements are not guarantees of performance. All forward-looking statements included in this document are based upon information available to the Company as of the date of this document, and the Company assumes no obligation to update.
OVERVIEW
Benchmark Electronics, Inc. (the Company) is a Texas corporation that provides design engineering and advanced manufacturing services that include both electronic manufacturing services (EMS) and precision technology (PT) services. We support customers throughout their product lifecycle starting from initial product concept through volume production, including the ability to manage direct order fulfillment and provide aftermarket services. We are a trusted partner to our European and U.S. based national and multi-national original equipment manufacturers (OEMs). Served markets include: aerospace and defense (A&D), medical, industrial, semiconductor capital equipment (Semi-Cap), and advanced computing and communication (AC&C). The Company has manufacturing operations located in the United States and Mexico (the Americas), Asia and Europe.
Our customer engagement focuses on three principal areas:
23
Our core strength lies in our ability to partner with our customers to provide concept-to-production solutions through a tightly integrated and seamless set of design, test, manufacturing, supply chain, and support services. The integration of these product realization services, along with our global manufacturing presence, increases our ability to respond to our customers’ needs by providing accelerated time-to-market and time-to-volume production of high-quality products with an emphasis on complex products serving regulated markets with higher reliability requirements. These capabilities and attributes enable us to build strong strategic relationships with our customers while becoming an integral part of their business.
We believe our primary source of differentiation and value-add rests with our ability to engage with our customers at any point, from product development through volume production. This is enabled by our highly skilled personnel’s ability to provide leading-edge technical capabilities in engineering services (including full lifecycle), high-frequency RF solutions, microelectronics, optics, miniaturization, and manufacturing services (including electronics and complex precision machining). These capabilities are brought to bear across diversified commercial end-markets, many of which are government regulated. To support customers across these sectors, we have strategically invested in geographically diverse manufacturing locations and global supply chain capabilities.
In addition, we believe that a strong focus on human capital through the talent we hire and retain is critical to maintaining our competitiveness. Our people-first culture is centered on our five core values, consisting of acting with integrity, valuing inclusion, commitment to customers, promoting ingenuity, and genuine caring for each other, our customers and our communities, and we take pride in our innovative and continuous improvement mindset. Our intent is to delight our customers while delivering operational and financial performance aligned with our goals. Through our employee engagement and customer satisfaction feedback processes, we continuously solicit and act upon information to improve our Company and better support our customers and business processes. We have invested in attracting and developing leadership throughout the organization and are committed to investing in an innovative and forward-thinking workforce.
Our customers often face challenges in designing supply chains, demand planning, procuring materials and managing their inventories efficiently due to fluctuations in their customer demand, product design changes, short product life cycles and component price fluctuations.
We employ enterprise resource planning (ERP) systems and lean/six sigma methodologies to manage procurement and manufacturing processes in an efficient and cost-effective manner so that, where possible, components arrive on a just-in-time, as-and-when-needed basis. Because we are a significant purchaser of electronic components and other raw materials, we are generally able to capitalize on the economies of scale associated with our relationships with suppliers to negotiate price discounts, obtain components and other raw materials that are in short supply, and return excess components. Utilizing our agility and expertise in supply chain management and our relationships with suppliers across the supply chain, we strive to help reduce our customers’ cost of goods sold and inventory exposure.
We recognize manufacturing services revenue as the customer takes control of the manufactured products built to customer specifications. We also generate revenue from our design, development and engineering services, in addition to the sale of other inventory.
Revenue is measured based on the consideration specified in a contract with a customer. Under the majority of our manufacturing contracts with customers, the customer controls all of the work-in-progress as products are being built. Revenues under these contracts are recognized progressively based on the cost-to-cost method. For other manufacturing contracts, the customer does not take control of the product until it is completed. Under these contracts, we recognize revenue upon transfer of control of the product to the customer, which is generally when the goods are shipped. Revenue from design, development and engineering services is recognized over time as the services are performed. As a general matter, we assume no significant obligations after shipment as we typically warrant workmanship only. Therefore, the warranty provisions are generally not significant.
24
Second Quarter of 2025 Highlights
Sales for the three months ended June 30, 2025 were $642.3 million, a 4% decrease from sales of $665.9 million during the three months ended June 30, 2024. During the second quarter of 2025, sales to customers in our various industry sectors varied from the second quarter of 2024 as follows:
Semi-Cap increased by 11%
Industrial remained flat
A&D increased by 16%
Medical decreased by 2%
AC&C decreased by 44%
The overall revenue decrease was primarily due to lower AC&C revenue, due to general end demand softness. This was partially offset by an increase in Semi-Cap and A&D revenue, due to improving demand and new customer wins. See “Results of Operations — Sales” discussion below.
Impact of Certain Factors on Results
Our sales depend on the success of our customers, some of which operate in businesses associated with rapid technological change and consequent product obsolescence. Developments adverse to our major customers or their products, the availability of electronic component supply, or the failure of a major customer to pay for components or services have adversely affected us by not allowing us to fulfill our total customer demand. A substantial percentage of our sales are made to a small number of customers, and the loss of a major customer, if not replaced, would adversely affect us. Sales to our ten largest customers represented 53% of our total sales during both the six months ended June 30, 2025 and 2024. After a period of unprecedented global labor and supply disruptions, we have seen a general easing of certain material constraints across commodity categories, with the exception of older technologies where semiconductor OEMs are not adding incremental capacity. The lack of capacity regarding these older technologies could constrain our ability to produce the full demand forecasts we are receiving from customers needing those parts. We have experienced a significant reduction of non-cancellable and non-returnable business terms from our suppliers as lead times have improved significantly from previous highs.
We experience fluctuations in gross profit from period to period. Different programs contribute different gross profits depending on the type of services involved, location of production, size of the program, complexity of the product and level of material costs associated with the various products. Moreover, new programs can contribute relatively less to our gross profit in their early stages when manufacturing volumes are usually lower, resulting in inefficiencies and unabsorbed manufacturing overhead costs. During periods of low production volume, we generally have unabsorbed manufacturing overhead costs and reduced gross profit. Gross profit can also be impacted by higher costs associated with other situations, such as supply chain constraints. In addition, a number of our new program ramps require incremental investment during the launch and ramp phase, which can exert downward pressure on our gross profit.
Inflation, interest rates, disruption in the global economy and financial markets, geopolitical instability, and government actions related to trade policies, tariffs and immigration continue to create uncertainty. Although we are not aware of any specific event or circumstance that would require updates to our estimates or judgments or require us to revise the carrying values of our assets or liabilities as of the date we filed this Report, we continue to monitor the current economic environment and its potential impact on our business, results of operations or financial condition, as well as potential impact on our end customers whose demand for our products and services may be adversely impacted as a result of changes in policies by the U.S. or other governments, and closely manage our costs and capital resources so that we can respond appropriately as circumstances change. Our estimates may change as new events occur and additional information is obtained. Actual results could differ from these estimates under different assumptions or conditions.
25
RESULTS OF OPERATIONS
The following table presents the percentage relationship that certain items in our condensed consolidated statements of income bear to sales for the periods indicated.
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Sales |
|
|
100.0 |
% |
|
|
100.0 |
% |
|
|
100.0 |
% |
|
|
100.0 |
% |
Cost of sales |
|
|
89.9 |
|
|
|
89.8 |
|
|
|
90.0 |
|
|
|
89.9 |
|
Gross profit |
|
|
10.1 |
|
|
|
10.2 |
|
|
|
10.0 |
|
|
|
10.1 |
|
Selling, general and administrative expenses |
|
|
6.3 |
|
|
|
5.7 |
|
|
|
6.2 |
|
|
|
5.6 |
|
Amortization of intangible assets |
|
|
0.2 |
|
|
|
0.2 |
|
|
|
0.2 |
|
|
|
0.2 |
|
Restructuring charges and other costs |
|
|
0.4 |
|
|
|
0.2 |
|
|
|
1.1 |
|
|
|
0.4 |
|
Income from operations |
|
|
3.2 |
|
|
|
4.1 |
|
|
|
2.5 |
|
|
|
3.9 |
|
Other expense, net |
|
|
(0.6 |
) |
|
|
(1.0 |
) |
|
|
(0.5 |
) |
|
|
(1.0 |
) |
Income before income taxes |
|
|
2.6 |
|
|
|
3.1 |
|
|
|
2.0 |
|
|
|
2.9 |
|
Income tax expense |
|
|
2.4 |
|
|
|
0.8 |
|
|
|
1.6 |
|
|
|
0.8 |
|
Net income |
|
|
0.2 |
% |
|
|
2.3 |
% |
|
|
0.4 |
% |
|
|
2.1 |
% |
Sales
As noted above, sales for the second quarter of 2025 decreased 4% from the second quarter of 2024.
Sales are analyzed by management by market sector and by geographic segment, which reflect our reportable segments. Our global business development strategy is based on our targeted market sectors. Management measures operational performance and allocates resources on a geographic segment basis.
Sales by market sector were as follows:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Semi-Cap |
|
$ |
190,382 |
|
|
$ |
171,864 |
|
|
$ |
385,449 |
|
|
$ |
337,803 |
|
Industrial |
|
|
141,629 |
|
|
|
141,703 |
|
|
|
278,376 |
|
|
|
282,735 |
|
A&D |
|
|
126,255 |
|
|
|
108,840 |
|
|
|
248,111 |
|
|
|
214,674 |
|
Medical |
|
|
109,570 |
|
|
|
111,551 |
|
|
|
213,207 |
|
|
|
226,278 |
|
AC&C |
|
|
74,499 |
|
|
|
131,938 |
|
|
|
148,956 |
|
|
|
279,981 |
|
Total net sales |
|
$ |
642,335 |
|
|
$ |
665,896 |
|
|
$ |
1,274,099 |
|
|
$ |
1,341,471 |
|
Semiconductor Capital Equipment. Sales for the three months ended June 30, 2025 increased 11% to $190.4 million from $171.9 million for the three months ended June 30, 2024. Sales for the six months ended June 30, 2025 increased 14% to $385.4 million from $337.8 million for the six months ended June 30, 2024. The increases were primarily due to higher demand and new program wins.
Industrial. Sales for the three months ended June 30, 2025 and 2024 were $141.6 million and $141.7 million, respectively. Sales for the six months ended June 30, 2025 decreased 2% to $278.4 million from $282.7 million for the six months ended June 30, 2024. The decrease was primarily due to demand softness from certain existing customers partially offset by new program ramps.
Aerospace and Defense. Sales for the three months ended June 30, 2025 increased 16% to $126.3 million from $108.8 million for the three months ended June 30, 2024. Sales for the six months ended June 30, 2025 increased 16% to $248.1 million from $214.7 million for the six months ended June 30, 2024. The increases were primarily due to strong market growth in both commercial aerospace and defense.
Medical. Sales for the three months ended June 30, 2025 decreased 2% to $109.6 million from $111.6 million for the three months ended June 30, 2024. Sales for the six months ended June 30, 2025 decreased 6% to $213.2 million from $226.3 million for the six months ended June 30, 2024. The decreases were primarily due to end-demand weakness impacting medical devices and delayed ramp of new programs.
26
Advanced Computing and Communications. Sales for the three months ended June 30, 2025 decreased 44% to $74.5 million from $131.9 million for the three months ended June 30, 2024. Sales for the six months ended June 30, 2025 decreased 47% to $149.0 million from $280.0 million for the six months ended June 30, 2024. The decreases were primarily due to lower demand coupled with high-performance computing program transitions.
Our international operations are subject to the risks of doing business abroad. See Part I, Item 1A of our 2024 10-K for factors pertaining to our international sales, fluctuations in foreign currency exchange rates and a discussion of potential adverse effects in operating results associated with the risks of doing business abroad. During the three months ended June 30, 2025 and 2024, 64% and 61%, respectively of our sales were from international operations.
Sales by geographic segment were as follows:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Sales: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Americas |
|
$ |
295,217 |
|
|
$ |
343,141 |
|
|
$ |
579,495 |
|
|
$ |
715,470 |
|
Asia |
|
|
287,066 |
|
|
|
257,670 |
|
|
|
571,105 |
|
|
|
515,486 |
|
Europe |
|
|
83,399 |
|
|
|
85,856 |
|
|
|
169,678 |
|
|
|
166,352 |
|
Elimination of intersegment sales |
|
|
(23,347 |
) |
|
|
(20,771 |
) |
|
|
(46,179 |
) |
|
|
(55,837 |
) |
Total sales |
|
$ |
642,335 |
|
|
$ |
665,896 |
|
|
$ |
1,274,099 |
|
|
$ |
1,341,471 |
|
Americas. Sales for the three months ended June 30, 2025 decreased 14% to $295.2 million from $343.1 million for the three months ended June 30, 2024. Sales for the six months ended June 30, 2025 decreased 19% to $579.5 million from $715.5 million for the six months ended June 30, 2024. The decreases were primarily due to softness in AC&C and Semi-Cap sectors partially offset by increased demand in the A&D sector.
Asia. Sales for the three months ended June 30, 2025 increased 11% to $287.1 million from $257.7 million for the three months ended June 30, 2024. Sales for the six months ended June 30, 2025 increased 11% to $571.1 million from $515.5 million for the six months ended June 30, 2024. The increases were primarily due to an increase in existing customer demand in the Semi-Cap and industrial sectors partially offset by decreased demand in the Medical and AC&C sectors.
Europe. Sales for the three months ended June 30, 2025 decreased 3% to $83.4 million from $85.9 million for the three months ended June 30, 2024. The decrease was primarily due to decreased demand in the Semi-Cap sector partially offset by an increase in the A&D sector. Sales for the six months ended June 30, 2025 increased 2% to $169.7 million from $166.4 million for the six months ended June 30, 2024. The increase was primarily due to higher demand in the A&D and Industrial sectors partially offset by a decrease in the Semi-Cap sector.
Gross Profit
Gross profit for the three months ended June 30, 2025 decreased 5% to $64.8 million from $68.0 million for the three months ended June 30, 2024. The decrease was primarily due to lower sales. Gross profit margin decreased to 10.1% for the three months ended June 30, 2025 from 10.2% for the three months ended June 30, 2024.
Gross profit for the six months ended June 30, 2025 decreased 5% to $128.0 million from $135.4 million for the six months ended June 30, 2024. The decrease was primarily due to lower sales. Gross profit margin decreased to 10.0% for the six months ended June 30, 2025 from 10.1% for the six months ended June 30, 2024.
27
Income from Operations
Income from operations for the three months ended June 30, 2025 decreased 25% to $20.5 million from $27.3 million in the three months ended June 30, 2024. Income from operations for the six months ended June 30, 2025 decreased 39% to $32.2 million from $52.8 million in the six months ended June 30, 2024. The decreases were primarily due to lower sales, as well as increased selling, general and administrative expenses primarily due to higher stock based compensation expense and increased restructuring expenses and other costs due to settlement of a tax assessment in the Americas as described below.
Income from operations by reportable segment was as follows:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Income from operations: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Americas |
|
$ |
10,777 |
|
|
$ |
13,186 |
|
|
$ |
6,349 |
|
|
$ |
23,353 |
|
Asia |
|
|
33,832 |
|
|
|
32,129 |
|
|
|
72,469 |
|
|
|
65,906 |
|
Europe |
|
|
6,649 |
|
|
|
6,628 |
|
|
|
14,652 |
|
|
|
13,405 |
|
Corporate and intersegment eliminations |
|
|
(30,772 |
) |
|
|
(24,690 |
) |
|
|
(61,225 |
) |
|
|
(49,882 |
) |
Total income from operations |
|
$ |
20,486 |
|
|
$ |
27,253 |
|
|
$ |
32,245 |
|
|
$ |
52,782 |
|
Americas. Income from operations for the three months ended June 30, 2025 decreased 18% to $10.8 million from $13.2 million for the three months ended June 30, 2024. Income from operations for the six months ended June 30, 2025 decreased 73% to $6.3 million from $23.4 million for the six months ended June 30, 2024.The decreases were primarily due to lower revenue, as well as increased restructuring expenses and other costs due to settlement of a tax assessment, partially offset by cost control. See Note 15 to the unaudited condensed consolidated financial statements in Part I, Item 1 of this Report for additional information on the tax assessment.
Asia. Income from operations for the three months ended June 30, 2025 increased 5% to $33.8 million from $32.1 million for the three months ended June 30, 2024. Income from operations for the six months ended June 30, 2025 increased 10% to $72.5 million from $65.9 million for the six months ended June 30, 2024. The increases were primarily due to higher revenue and cost control.
Europe. Income from operations for the three months ended June 30, 2025 was flat at $6.6 million for the three months ended June 30, 2024. Income from operations for the six months ended June 30, 2025 increased 9% to $14.7 million from $13.4 million for the six months ended June 30, 2024. The increases were primarily due to higher revenue and cost control.
Selling, General and Administrative Expenses
SG&A expenses increased to $40.6 million for the three months ended June 30, 2025 from $38.0 million for the three months ended June 30, 2024. SG&A expenses increased to $79.4 million for the six months ended June 30, 2025 from $75.4 million for the six months ended June 30, 2024. The increases were primarily due to higher stock based compensation expense, as well as professional services.
Amortization of Intangible Assets
Amortization of intangible assets was $1.2 million for the three months ended June 30, 2025 and 2024. Amortization of intangible assets was $2.4 million for the six months ended June 30, 2025 and 2024.
28
Restructuring Charges and Other Costs
During the three and six months ended June 30, 2025, we recognized $1.9 million and $3.3 million, respectively, of restructuring charges and other costs primarily due to capacity and workforce reductions at our sites in the Americas. Additionally, the Company incurred $0.6 million and $10.7 million of settlement costs related to a tax assessment in the Americas for the three and six months ended June 30, 2025, respectively. See Note 15 to the unaudited condensed consolidated financial statements in Part I, Item 1 of this Report for additional information on the tax assessment.
During the three and six months ended June 30, 2024, we recognized $1.5 million and $4.8 million, respectively, of restructuring charges and other costs primarily due to capacity and workforce reductions at our sites in the Americas.
See Note 16 to the unaudited condensed consolidated financial statements in Part I, Item 1 of this Report for additional information on our restructuring charges and other costs.
Interest Expense
Interest expense decreased to $6.3 million for the three months ended June 30, 2025 from $6.9 million for the three months ended June 30, 2024. Interest expense decreased to $11.6 million for the six months ended June 30, 2025 from $14.2 million for the six months ended June 30, 2024. The decreases were primarily due to decreased borrowings and a lower interest rate environment.
Interest Income
Interest income increased to $3.1 million for the three months ended June 30, 2025 from $2.5 million for the three months ended June 30, 2024. Interest income increased to $5.9 million for the six months ended June 30, 2025 from $4.5 million for the six months ended June 30, 2024. The increases were primarily due to higher cash balances partially offset by a lower interest environment.
Other Expense, Net
Other expense, net decreased to $0.7 million for the three months ended June 30, 2025 from $2.3 million for the three months ended June 30, 2024. Other expense, net decreased to $1.5 million for the six months ended June 30, 2025 from $3.5 million for the six months ended June 30, 2024. The decreases were primarily due to lower foreign currency exchange losses.
Income Tax Expense
Income tax expense of $15.6 million represented a 94.1% effective tax rate for the three months ended June 30, 2025, compared with $5.0 million for the three months ended June 30, 2024, representing an effective tax rate of 24.3%. Income tax expense of $20.4 million represented a 81.5% effective tax rate for the six months ended June 30, 2025, compared with $10.1 million for the six months ended June 30, 2024, representing an effective tax rate of 25.5%. The increase in the effective tax rate in 2025 is primarily due to the $10.4 million in discrete tax expense recorded in the second quarter for the foreign withholding taxes on repatriated dividends and recognition of deferred tax liabilities on China unremitted earnings, losses generated in a jurisdiction where no tax benefit can be recognized and to the mix of profits in our various jurisdictions.
Net Income
We reported net income of $1.0 million, or $0.03 per diluted share, for the three months ended June 30, 2025, compared with net income of $15.5 million, or $0.43 per diluted share, for the three months ended June 30, 2024. We reported net income of $4.6 million, or $0.13 per diluted share, for the six months ended June 30, 2025, compared with net income of $29.5 million, or $0.81 per diluted share, for the six months ended June 30, 2024. The decreases were primarily due to the items discussed above.
29
LIQUIDITY AND CAPITAL RESOURCES
We have historically financed our organic growth and operations through funds generated from operations and occasional borrowings under our credit agreement (as amended and restated, the Credit Agreement), consisting of a term loan facility and a $550.0 million revolving credit facility, both with a maturity date of June 27, 2030. Cash, cash equivalents and restricted cash totaled $264.6 million as of June 30, 2025, which included $227.5 million held outside the United States in various foreign subsidiaries.
Management believes that our existing cash balances, funds generated from operations, and borrowing availability under our revolving credit facility will be sufficient to permit us to meet our liquidity requirements over the next 12 months. Management further believes that our ongoing cash flows from operations and any borrowings we may incur under our revolving credit facility will enable us to meet operating cash requirements in future years. If we consummate significant acquisitions in the future, our capital needs would increase and could possibly result in our need to increase available borrowings under our Credit Agreement or access public or private debt and equity markets. There can be no assurance, however, that we would be successful in raising additional debt or equity on acceptable terms.
Cash Flows
Cash provided from operating activities was $28.7 million during the six months ended June 30, 2025, and primarily consisted of $4.6 million of net income, adjusted for $23.8 million of depreciation and amortization, $9.7 million of stock-based compensation expense, a $46.8 million decrease in accounts receivable, a $26.1 million decrease in inventories, partially offset by a $17.7 million decrease in accrued liabilities, a $17.2 million decrease in advance payments from customers and a $20.7 million decrease in income taxes. Working capital was $0.8 billion as of June 30, 2025.
We primarily purchase components only after customer orders or forecasts are received, which mitigates, but does not eliminate, the risk of loss on inventories. Supplies of electronic components and other materials used in operations are subject to industry-wide shortages. In certain instances, suppliers may allocate available quantities to us. When shortages of these components and other material supplies used in operations have occurred, vendors have at times been unable to ship the quantities we need for production, forcing us to delay shipments, which can increase backorders and impact cash flows. Vendors also may increase the costs of components based on the market conditions including these shortages. In certain instances, we request and receive advance payments from customers as prepayments of inventory to meet working capital demands of a contract, offset inventory risks such as inventory purchased in advance of current needs and protect the Company from the failure of other parties to fulfill obligations under a contract. For example, we have been impacted by supply chain constraints, including shortages, longer lead times and increased transit times. Furthermore, the U.S. government’s adoption of new approaches to trade policy and imposition of tariffs on certain foreign goods (as well as the possibility of imposing significant, additional tariffs in the future) may make it more difficult or costly for us to procure components and other material supplies and, in turn, may increase the cost to our customers, which may materially and adversely impact demand for our products and services, our results of operations or our financial condition.
Cash used in investing activities was $16.4 million during the six months ended June 30, 2025 primarily due to capital expenditures for property, plant and equipment of $14.4 million and purchased software of $2.1 million. The purchases of property, plant and equipment were primarily for leasehold improvements and machinery and equipment in the Americas and Asia.
Cash used in financing activities was $85.4 million during the six months ended June 30, 2025. Borrowings under the Credit Agreement were $398.6 million and principal payments under the Credit Agreement were $446.6 million. In addition, during the six months ended June 30, 2025, we paid $16.0 million for stock repurchases, $6.7 million for employee taxes in connection with the settlement of stock-based awards and $12.3 million for dividends.
Credit Agreement
On June 27, 2025, the Company entered into a $700 million second amended and restated credit agreement (the Credit Agreement) by and among the Company, certain of its subsidiaries, the lenders party thereto and Bank of America, N.A., as Administrative Agent, Swingline Lender and an L/C Issuer. The Credit Agreement is comprised of a five-year $550 million revolving credit facility and a five-year $150 million term loan facility, both with a maturity date of June 27, 2030. As of June 30, 2025, we had $150 million in borrowings outstanding under the term loan facility, $60.0 million outstanding under our revolving credit facility and $4.4 million in letters of credit outstanding under our revolving credit facility. See Note 5 to the unaudited condensed consolidated financial statements in Part I, Item 1 of this Report for more information regarding the terms of our Credit Agreement.
30
The Credit Agreement contains certain financial covenants related to interest coverage and debt leverage, and certain customary affirmative and negative covenants, including restrictions on our ability to incur additional debt and liens, pay dividends, repurchase shares, sell assets, including trade accounts receivable, and merge or consolidate with other persons. Amounts due under the Credit Agreement could be accelerated upon specified events of default, including a failure to pay amounts due, breach of a covenant, material inaccuracy of a representation, or occurrence of bankruptcy or insolvency, subject, in some cases, to cure periods. As of June 30, 2025, we were in compliance with all of these covenants and restrictions.
As of June 30, 2025, we had $485.6 million available for borrowings under the Credit Agreement, subject to compliance with financial covenants as to interest coverage and debt leverage, in addition to other debt covenant restrictions. During the next 12 months, we believe our capital expenditures will approximate $60 million to $70 million, principally for machinery and equipment to help increase our production capacity to support anticipated revenue growth and our ongoing business around the globe.
Dividends
During the six months ended June 30, 2025 and 2024, cash dividends paid totaled $12.3 million and $11.8 million, respectively. On June 9, 2025, the Board of Directors declared a quarterly cash dividend of $0.17 per share of the Company’s common stock to shareholders of record as of June 30, 2025. The dividend of $6.1 million was paid on July 11, 2025.
The Board of Directors currently intends to continue paying quarterly dividends. However, the Company’s future dividend policy is subject to the Company’s compliance with applicable law, and dependent on, among other things, the Company’s results of operations, financial condition, level of indebtedness, capital requirements, contractual restrictions, restrictions in the Company’s debt agreements, and other factors that the Board of Directors may deem relevant. Dividend payments are not mandatory or guaranteed; there can be no assurance that the Company will continue to pay a dividend in the future.
Share Repurchase Authorization
On February 19, 2020, the Board of Directors approved an expanded share repurchase authorization granting the Company authority to repurchase up to $150 million in common stock.
The Company repurchased 0.4 million shares for an aggregate of $16.0 million at an average price of $37.43 per share during the six months ended June 30, 2025. As of June 30, 2025, the Company had $133.5 million remaining under share repurchase authorizations. See Note 7 to the unaudited condensed consolidated financial statements in Part I, Item 1 of this Report for more information on the share repurchase authorization.
CONTRACTUAL OBLIGATIONS
We have certain contractual obligations for operating leases that were summarized in “Contractual Obligations” under Part II, Item 7 in our 2024 10-K. Other than items discussed in Note 5 and Note 6 to the unaudited condensed consolidated financial statements in Part I, Item 1 of this Report, there have been no material changes to our contractual obligations, outside of the ordinary course of our business, since December 31, 2024.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES AND RECENTLY ENACTED ACCOUNTING PRINCIPLES
Management’s discussion and analysis of financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. See Note 2 to the unaudited condensed consolidated financial statements in Part I, Item 1 of this Report for a discussion of recently enacted accounting principles. Also, our significant accounting policies are summarized in Note 1 to the consolidated financial statements included in our 2024 10-K. There have been no changes to the items disclosed as critical accounting estimates in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of our 2024 10-K.
31
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Our international sales comprise a significant portion of our business. We are exposed to risks associated with operating internationally, including:
Additionally, some of our operations are in developing countries. Certain events, including natural disasters, can impact the infrastructure of a developing country more severely than they would impact the infrastructure of a developed country. A developing country can also take longer to recover from such events, which could lead to delays in our ability to resume full operations.
We transact business in various foreign countries and are subject to foreign currency fluctuation risks. We use natural hedging and forward contracts to economically hedge transactional exposure primarily associated with trade accounts receivable, other receivables and trade accounts payable that are denominated in a currency other than the functional currency of the respective operating entity. We do not use derivative financial instruments for speculative purposes. Certain forward currency exchange contracts in place as of June 30, 2025 have not been designated as accounting hedges and, therefore, changes in fair value are recorded within our unaudited condensed consolidated statements of income in Part I, Item 1 of this Report.
The Company enters into forward currency exchange contracts designated as cash flow hedges of forecasted foreign currency expenses. Changes in the fair value of the derivatives are recorded in accumulated other comprehensive loss on the condensed consolidated balance sheets until earnings are affected by the variability of the cash flows.
Our sales are substantially denominated in U.S. dollars. Our foreign currency cash flows are generated in certain European and Asian countries and Mexico.
We are also exposed to market risk for changes in interest rates on our financial instruments, a portion of which relates to our invested cash balances. We do not use derivative financial instruments in our investing activities. We place cash and cash equivalents and investments with various major financial institutions. We protect our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by generally investing in investment grade securities.
We are also exposed to interest rate risk on borrowings under our Credit Agreement. As of June 30, 2025, we had $150 million outstanding on the floating rate term loan facility, and we have an interest rate swap agreement with a notional amount of $119.8 million and a fixed interest rate of 4.039%. Under this swap agreement, we receive variable rate interest rate payments and pay fixed rate interest payments. The effect of this swap is to convert our floating rate interest expense to a fixed interest rate expense. The interest rate swap is designated as a cash flow hedge.
For additional information regarding our forward currency exchange contracts and interest rate swap agreement, see Note 13 to the unaudited condensed consolidated financial statements in Part I, Item 1 of this Report.
Item 4. Controls and Procedures
As of the end of the period covered by this Report, the Company’s management (with the participation of our Chief Executive Officer (CEO) and Chief Financial Officer (CFO)) conducted an evaluation pursuant to Rule 13a-15 under the Exchange Act of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) of the Exchange Act). Based on this evaluation, the CEO and CFO concluded that as of the end of the period covered by this Report, such disclosure controls and procedures were effective at a reasonable assurance level to ensure that information required to be disclosed by the Company in reports it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to the Company’s management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.
There has been no change in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) or 15d-15(f) of the Exchange Act) that occurred during the last fiscal quarter covered by this Report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
32
We are currently upgrading our ERP system, which is expected to occur in phases over the next several years. We have completed the implementation of the upgrades at certain of the Company’s locations and have revised and updated the related controls. These changes did not materially affect our internal control over financial reporting. As we implement the upgrades of this ERP system at the remaining locations over the next several years, we will continue to assess the impact on our internal control over financial reporting.
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by individuals’ acts, by collusion of two or more people, or by management overriding the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, a control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
33
PART II—OTHER INFORMATION
Item 1. Legal Proceedings
We are involved in various legal actions arising in the ordinary course of business. See discussion under Note 15 to the unaudited condensed consolidated financial statements in Part I, Item 1 of this Report, which is incorporated by reference herein.
Item 1A. Risk Factors
There have been no material changes to the risk factors previously disclosed in Part I, Item 1A of our 2024 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(c) The following table provides information for the three months ended June 30, 2025 about the Company’s repurchases of its equity securities registered pursuant to Section 12 of the Exchange Act:
|
|
|
|
|
|
|
|
|
|
|
(d) |
|
||||
|
|
|
|
|
|
|
|
(c) |
|
|
Maximum |
|
||||
|
|
|
|
|
|
|
|
Total |
|
|
Number (or |
|
||||
|
|
|
|
|
|
|
|
Number of |
|
|
Approximate |
|
||||
|
|
|
|
|
|
|
|
Shares (or Units) |
|
|
Dollar Value) of |
|
||||
|
|
(a) |
|
|
|
|
|
Purchased as |
|
|
Shares (or Units) |
|
||||
|
|
Total |
|
|
(b) |
|
|
Part of Publicly |
|
|
that May Yet Be |
|
||||
|
|
Number of |
|
|
Average Price |
|
|
Announced |
|
|
Purchased Under |
|
||||
|
|
Shares (or Units) |
|
|
Paid per Share |
|
|
Plans or |
|
|
the Plans or |
|
||||
(amounts in millions, except share and per share data) |
|
Purchased |
|
|
(or Unit) |
|
|
Programs |
|
|
Programs (1) |
|
||||
April 1 to 30, 2025 |
|
|
— |
|
|
$ |
— |
|
|
|
— |
|
|
$ |
141.5 |
|
May 1 to 31, 2025 |
|
|
224,635 |
|
|
|
35.58 |
|
|
|
224,635 |
|
|
|
133.5 |
|
June 1 to 30, 2025 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
133.5 |
|
Total |
|
|
224,635 |
|
|
|
35.58 |
|
|
|
224,635 |
|
|
|
133.5 |
|
(1) On December 7, 2015, the Board of Directors approved a share repurchase authorization granting the Company authority to repurchase up to $100 million in common stock. On March 6, 2018, October 26, 2018 and February 19, 2020, the Board of Directors authorized the repurchase of an additional $250 million, $100 million and $150 million of the Company’s common stock, respectively. Stock purchases may be made in the open market, in privately negotiated transactions or block transactions, at the discretion of the Company’s management and as market conditions warrant. Purchases are funded from available cash and may be commenced, suspended or discontinued at any time without prior notice. Shares of stock repurchased under the program are retired. The Company repurchased 0.2 million shares for an aggregate of $8.0 million at an average price of $35.58 per share during the three months ended June 30, 2025. As of June 30, 2025, the Company had $133.5 million remaining under share repurchase authorizations.
Item 5. Other Information
Rule 10b5-1 Plan Adoptions and Modifications
During the three months ended June 30, 2025, no director or officer
34
Item 6. Exhibits
Exhibit No. |
|
Exhibit Description |
|
|
|
3.1 |
|
Restated Certificate of Formation dated May 17, 2016 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K dated May 17, 2016) (the 8-K) (Commission file number 1-10560) |
|
|
|
3.2 |
|
Amended and Restated Bylaws of the Company dated December 2, 2020 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K dated December 7, 2020 (Commission file number 1-10560)) |
|
|
|
4.1 |
|
Specimen form of certificate evidencing the Common Shares (incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014) (Commission file number 1-10560) |
|
|
|
10.1 |
|
Second Amended and Restated Credit Agreement, dated June 27, 2025, by and among Benchmark Electronics, Inc., certain of its subsidiaries, the lenders party thereto and Bank of America, N.A., as Administrative Agent, Swingline Lender and an L/C Issuer* (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 30, 2025 (Commission file number 1-10560)) |
|
|
|
31.1 (1) |
|
Section 302 Certification of Chief Executive Officer |
|
|
|
31.2 (1) |
|
Section 302 Certification of Chief Financial Officer |
|
|
|
32.1 (2) |
|
Section 1350 Certification of Chief Executive Officer |
|
|
|
32.2 (2) |
|
Section 1350 Certification of Chief Financial Officer |
|
|
|
101.INS (1) |
|
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
|
|
|
101.SCH (1) |
|
Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents |
|
|
|
104 (1) |
|
Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document (included in Exhibit 101) |
* Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish supplementally to the Securities and Exchange Commission a copy of any omitted exhibits or schedules upon request.
(1) Filed herewith
(2) Furnished herewith
35
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on July 31, 2025.
|
BENCHMARK ELECTRONICS, INC. |
||
|
|
||
|
(Registrant) |
||
|
|
|
|
|
By: |
|
/s/ Jeffrey W. Benck |
|
|
|
Jeffrey W. Benck |
|
|
|
President and Chief Executive Officer |
|
|
|
(Principal Executive Officer) |
|
|
||
|
By: |
|
/s/ Bryan R. Schumaker |
|
|
|
Bryan R. Schumaker |
|
|
|
Chief Financial Officer |
|
|
|
(Principal Financial and Accounting Officer) |
36
Source:
FAQ
How many SEM shares did the CIO acquire on 29-Jul-2025?
What is Brian R. Rusignuolo鈥檚 total ownership after the grant?
When will the restricted stock granted to SEM鈥檚 CIO vest?
Was the transaction an open-market purchase?
Does the filing mention any derivative securities?
